TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18366445
Drug: Nevirapine-containing combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine-containing combination antiretroviral therapy (NcART)
Study: 15695788
Drug: Intravenous iodinated
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous iodinated contrast agent (used in part I and part II)
Study: 15695788
Drug: Limited plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited plain CT scan followed by WB intravenous contrast CT scan (used in part II)
Study: 12642963
Drug: Sugar-coated tablet
Normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar-coated tablet (50 mg opipramol-2HCl)
Study: 12642963
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution (50 mg opipramol-2HCl)
Study: 12642963
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet (100 mg opipramol-2HCl)
Study: 12642963
Drug: Sugar-coated tablet
Normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar-coated tablet (100 mg opipramol-2HCl)
Study: 11220871
Drug: Grandaxine in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grandaxine in combination with standard therapy
Study: 8641115
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg day‐1
Study: 24729586
Drug: CYP2A6 -48T→G
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2A6 -48T→G polymorphism
Study: 24729586
Drug: UGT2B7 735
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGT2B7 735 G/G homozygosity
Study: 24729586
Drug: CYP2A6 -48T→G
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2A6 -48T→G and UGT2B7 735 G/G homozygosity (multivariable model)
Study: 22335390
Drug: DEX 0.5
Normalized name: Stri-Dex 0.5 % Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 0.5 μg/kg in 10 mL isotonic saline
Study: 22335390
Drug: DEX 1
Normalized name: Z-Dex 12 D
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX 1 μg/kg in 10 mL isotonic saline
Study: 22335390
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL isotonic saline (control group)
Study: 16642609
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (acupuncture + Xingnaojing injection)
Study: 1584592
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (5 ml of 2% lidocaine)
Study: 1584592
Drug: Saline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (5 ml saline)
Study: 29534465
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement (whey isolate and beef hydrolysate)
Study: 22235888
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing niosomes entrapped with rice bran bioactive compounds
Study: 22235888
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing niosomes entrapped with rice bran bioactive compounds
Study: 22235888
Drug: Closed patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed patch test on shaved rabbit skin
Study: 18520803
Drug: ABT‐751 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐751 200 mg daily for 21 consecutive days, followed by 7 days off drug
Study: 16529564
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (pelvic floor muscle training and duloxetine)
Study: 1346745
Drug: verapamil 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 0.05 mg kg‐1
Study: 1346745
Drug: verapamil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 0.1 mg kg‐1
Study: 1346745
Drug: verapamil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (both doses)
Study: 6513620
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) in phase 1, then received concurrent reminders in phase 2
Study: 30373781
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus tablets combined with quadruple therapy
Study: 25233647
Drug: Guan's quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guan's quadruple therapy for kidney disease
Study: 22622628
Drug: Methylphenidate administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate administered for one week
Study: 18666804
Drug: FDC tablet
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC tablet of repaglinide/metformin 2 mg/500 mg
Study: 16883914
Drug: Radix Astragali
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix Astragali Injection
Study: 16883914
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (control)
Study: 8828744
Drug: Higher-dose didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose didanosine (750 mg per day for patients > or = 60 kg)
Study: 8828744
Drug: Lower-dose didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose didanosine (200 mg per day)
Study: 8828744
Drug: Higher-dose didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose didanosine
Study: 8828744
Drug: Lower-dose didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose didanosine
Study: 27138022
Drug: Single-dose study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose study
Study: 27138022
Drug: Multiple-dose study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose study
Study: 3544186
Drug: Pirenzepine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (10 mg)
Study: 3933861
Drug: Pirenzepine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (30 mg)
Study: 3933861
Drug: Pirenzepine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (40 mg)
Study: 31223014
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment method from 2000-2005
Study: 28028723
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SFI) treatment (100 mL/24 h)
Study: 25576680
Drug: <2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: <2 g sodium diet education
Study: 25576680
Drug: <2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: <2 g sodium diet education (2 samples)
Study: 23364361
Drug: Sedative instrumental
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative instrumental music (60-80 beats per minute)
Study: 9416888
Drug: Lisinopril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (2.5 to 5 up to 10 mg/d) with or without nitroglycerin (5 to 20 microg I.V. then 10 mg/d)
Study: 8269890
Drug: Vegan diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegan diet (uncooked 'living food') for 3 months, tutored daily by a living-food expert.
Study: 3114203
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) 500 micrograms
Study: 23671022
Drug: Coffee 6
Normalized name: Coffee, green
DrugBank: Arabica coffee bean (DB10666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee 6 (6 mg caffeine/kg body weight)
Study: 23671022
Drug: Coffee 3
Normalized name: Coffee, green
DrugBank: Arabica coffee bean (DB10666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee 3 (3 mg caffeine/kg body weight)
Study: 19131132
Drug: G‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (10 microg/kg/day)
Study: 16893641
Drug: Preoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative concurrent chemoradiotherapy (5‐fluorouracil (5‐FU) 500 mg/m2/d continuous infusion for 4 cycles and vinorelbine 25 mg/m2 on specific days)
Study: 16893641
Drug: Preoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative concurrent chemoradiotherapy
Study: 11293237
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg i.v. monthly
Study: 8864319
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 800 mg given twice daily for 28 days
Study: 1735313
Drug: PSK (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK (oral) for over three years, mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months.
Study: 1735313
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C intravenously on the day of and the day after surgery, followed by oral 5-fluorouracil (5-FU) for over six months.
Study: 6122188
Drug: Lorazepam (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3.0 mg)
Study: 30420479
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg once daily) with artemether-lumefantrine
Study: 30420479
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg once daily) with artesunate-amodiaquine
Study: 26966119
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of DAR-0100A
Study: 26966119
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of DAR-0100A
Study: 11722957
Drug: Excess dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Excess dietary cysteine (21 mg x kg(‐1) x d(‐1))
Study: 9135425
Drug: Textured silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Textured silicone gel-filled implants
Study: 9135425
Drug: Smooth silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth silicone gel-filled implants
Study: 8189476
Drug: rhGH (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.15 mg/kg/day, Somatropin, Genentech, Inc.)
Study: 3555687
Drug: Single-dose cefotaxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose cefotaxime
Study: 3555687
Drug: Single-dose cephradine
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cephradine
Study: 31297582
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids (Group T, n: 42)
Study: 31297582
Drug: Systemic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids (0.8 mg/kg/day peroral, Group S, n: 42)
Study: 31297582
Drug: Combined steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined steroids (0.4 mg/kg/day peroral + topical, Group C, n: 40)
Study: 28891198
Drug: Targeted medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted medical nutrition (TMN) - 230 kcal; 2 g omega-3 fatty acids; 10 μg 25-hydroxy-vitamin D3, administered twice daily for 12 weeks.
Study: 28891198
Drug: Isocaloric comparator,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric comparator, administered twice daily for 12 weeks.
Study: 28273329
Drug: Paper mode
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper mode of administration
Study: 28273329
Drug: Electronic mode
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic mode of administration
Study: 28273329
Drug: Mixed-mode administration
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-mode administration
Study: 25354927
Drug: Web-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based behavioral activation intervention (Bounce Back Now); specific dosage and duration not mentioned.
Study: 22490629
Drug: Intensive antiplatelet
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive antiplatelet therapy (double maintenance dose of clopidogrel 150 mg/d and aspirin 300 mg/d, followed by cilostazol 50-100 mg bid if HPR persists)
Study: 22490629
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet therapy (aspirin 300 mg/d and clopidogrel 75 mg/d)
Study: 17697904
Drug: LID 40
Normalized name: linezolid 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LID 40 mg + MET 5 mg
Study: 17697904
Drug: LID 40
Normalized name: linezolid 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LID 40 mg + MET 10 mg
Study: 17697904
Drug: LID 40
Normalized name: linezolid 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LID 40 mg + MET 2.5 mg
Study: 1693007
Drug: Dakin solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dakin solution after 15 days of inefficacy of previous antiseptics
Study: 7281085
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with chemotherapy (adriamycin and 5-fluorouracil)
Study: 23252583
Drug: Piroxicam +
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam + Low-level laser therapy
Study: 15377583
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg kg(‐1) loading dose followed by 0.05 mg kg(‐1) min(‐1) infusion)
Study: 8026260
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice a day plus amoxicillin 1 g twice a day (group I, N = 30)
Study: 8026260
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice a day plus amoxicillin 1 g twice a day (group II, N = 30)
Study: 8026260
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice a day plus amoxicillin 1 g three times a day (group III, N = 30)
Study: 2574836
Drug: Atracurium (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (initial bolus 0.5 mg/kg, continuous infusion 5.5 micrograms/kg/min)
Study: 2574836
Drug: Vecuronium (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (initial bolus 0.08 mg/kg, continuous infusion 0.9 micrograms/kg/min)
Study: 2574836
Drug: Atracurium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium with prostigmin (0.04 mg/kg) in recovery phase
Study: 2574836
Drug: Vecuronium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium with prostigmin (0.04 mg/kg) in recovery phase
Study: 31996926
Drug: High-volume hemofiltration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume hemofiltration continuous renal replacement therapy
Study: 28215362
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sirukumab every 4 weeks
Study: 28215362
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sirukumab every 2 weeks
Study: 18452749
Drug: Motor point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor point injection technique with 60U of BTX‐A (Botox) in 2.4mL or 30U BTX‐A in 1.2mL of saline
Study: 18452749
Drug: Multisite distributed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisite distributed injection technique with 90U of BTX‐A in 3.6mL
Study: 12698647
Drug: Postoperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intravenous injection of Irinotekan (group 1)
Study: 12698647
Drug: Intraarterial regional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial regional injection of Irinotekan (group 2)
Study: 12698647
Drug: Intraarterial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial therapy with Irinotekan (group 3)
Study: 12698647
Drug: Systemic intravenous
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic intravenous therapy with Irinotekan (group 4)
Study: 10886044
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg as simplified omeprazole suspension
Study: 10886044
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg as simplified lansoprazole suspension
Study: 10886044
Drug: Omeprazole capsules
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole capsules
Study: 10886044
Drug: Lansoprazole capsules
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole capsules
Study: 9298736
Drug: Interferon alpha-2a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha-2a, 9 megaunits thrice weekly for six months
Study: 8373935
Drug: Aspartame 30
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame 30 mg/kg/day
Study: 3780838
Drug: Torasemide 20
Normalized name: Torasemide 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 20 mg and Furosemide 40 mg
Study: 31005204
Drug: Xelac: concomitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xelac: concomitant boost to bulky site (45 Gy/1.8 Gy/day, 5 sessions/week to the pelvis, +10 Gy at 1 Gy twice/week to the bulky) plus concurrent capecitabine (1650 mg/mq/day)
Study: 31005204
Drug: Xelox: 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xelox: 45 Gy to the pelvis + 5.4 Gy/1.8 Gy/day, 5 sessions/week to the bulky site + concurrent capecitabine (1300 mg/mq/day) and oxaliplatin (130 mg/mq on days 1, 19, 38)
Study: 12636463
Drug: Less than
Normalized name: IgA less than or equal to 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less than 1 drink weekly
Study: 12636463
Drug: 1 to
Normalized name: Cep-11981 tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 6 drinks weekly
Study: 12636463
Drug: 7 to
Normalized name: NP-27 Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 to 13 drinks weekly
Study: 12636463
Drug: 14 or
Normalized name: LACTOBACILLUS 14/14 ORAL & VAG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 or more drinks weekly
Study: 8794786
Drug: Tetraprenylacetone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetraprenylacetone (300 mg for four weeks)
Study: 1523076
Drug: Ceftibuten (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (5 days treatment)
Study: 1523076
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) (5 days treatment)
Study: 1523076
Drug: Ceftibuten and
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten and TMP-SMX (both treatments)
Study: 6823418
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk (185 mL/kg/d)
Study: 26720597
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg/day for 8 weeks
Study: 22424722
Drug: Nevirapine-based treatment
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine-based treatment after suppression with protease-inhibitor-based regimen
Study: 22424722
Drug: Protease-inhibitor-based treatment
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease-inhibitor-based treatment (ritonavir-boosted lopinavir)
Study: 20121419
Drug: Efavirenz therapy
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz therapy
Study: 10875030
Drug: Dofetilide (15-min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (15-min loading infusion of 4 g/kg followed by a 60-min maintenance infusion of 3.5 g/kg, total dose of 7.5 g/kg)
Study: 10875030
Drug: Placebo (single-blind
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (single-blind infusion)
Study: 8741938
Drug: Diazepam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (4 mg)
Study: 8741938
Drug: Buspirone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5 mg)
Study: 8428895
Drug: triazolam 0.5
Normalized name: triazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: triazolam 0.5 mg
Study: 6145178
Drug: withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: withdrawal of either drug after 3 weeks
Study: 30398602
Drug: Inhaled inorganic
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled inorganic nitrite (46 mg 3 times a day for 1 week followed by 80 mg 3 times a day for 3 weeks)
Study: 28476756
Drug: Inhaled inorganic
Normalized name: Organic germanium
DrugBank: Propagermanium (DB17608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled inorganic nitrite
Study: 22575544
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg I (as KI) daily throughout pregnancy
Study: 19092246
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol (40 mg for <70 years, 30 mg for ≥70 years)
Study: 19092246
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol vs. Midazolam
Study: 12360457
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg/day for 6 weeks
Study: 28857147
Drug: Aminophylline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (500 mg)
Study: 8970501
Drug: Valproate (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate (oral loading dosage)
Study: 8970501
Drug: Carbamazepine and
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine and lithium (combination treatment)
Study: 6433770
Drug: HB 419
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HB 419 (5 mg twice a day)